175 results
Page 3 of 9
424B3
m46svk1bh8
19 Jan 22
Prospectus supplement
4:05pm
8-K
poazvyvko7
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
EX-99.1
8dmaais9uj1w2fu6
12 Nov 21
7 of 16 (44%) patients achieved best overall response of partial response
7:06am
8-K
0hsmv l6zg
12 Nov 21
7 of 16 (44%) patients achieved best overall response of partial response
7:06am
8-K
EX-99.1
c9l0kvbwsd6
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
EX-99.2
rkitxnnmcepuluqkl
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
EX-99.1
t2zwgbl cbz659fwnkta
28 Oct 21
Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
4:06pm
8-K
67f0 ub3wc2otoi
9 Aug 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
7:09am
8-K
EX-99.1
ldw zwxre7zfliefq
9 Aug 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
7:09am
8-K
EX-99.1
27mxyj8ym3 5x39
5 Aug 21
Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
7:06am
8-K
EX-99.1
wbjiux9bjx10qev1
15 Jul 21
Aravive Achieves Second Development Milestone from 3D Medicines
7:05am
8-K
EX-99.1
pwypvh
24 Jun 21
Regulation FD Disclosure
7:07am
8-K
EX-10.1
tp11aaqed
14 Jun 21
Entry into a Material Definitive Agreement
4:08pm
8-K
EX-99.1
lmazr2s
18 May 21
Aravive Announces Three New Appointments to its Board of Directors
7:05am
8-K
EX-99.2
zg9dbk64 eldvzh1n71
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.1
ildo3ss3e50d6 kfbd
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am